What diseases or conditions qualify for the Breakthrough Devices Program?

FDA uses the terms "life-threatening" and "irreversibly debilitating." Cancers, advanced cardiovascular disease, end-stage renal disease, severe neurological conditions, conditions causing permanent blindness, and similar high-severity diagnoses have supported designation requests. There is no fixed list. FDA evaluates the disease characterization in each request.

Can a 510(k) device receive Breakthrough Device designation?

Yes, if it meets both eligibility criteria. Most 510(k) devices do not target life-threatening or irreversibly debilitating conditions, but devices in oncology diagnostics, cardiac monitoring, or neurological disease that happen to be Class II can qualify. The designation applies to the device and the regulatory pathway, not the other way around.

Does Breakthrough Device designation mean FDA will clear or approve the device faster?

Designation prioritizes the device in FDA's review queue and enables more interactive engagement during development. It does not guarantee a specific timeline or a favorable outcome. The device still must demonstrate safety and effectiveness. Designation changes the process, not the evidentiary standard.

How much does a Breakthrough Device designation request cost?

There is no FDA user fee specific to a Breakthrough Device designation request because it is submitted as a Pre-Submission (Q-Sub), and Q-Subs are not subject to user fees (as of July 2026). The cost is the internal and consultant time required to prepare the submission package.

Can a device lose its Breakthrough Device designation?

Yes. FDA can rescind a designation if the device no longer meets the eligibility criteria, if the sponsor requests rescission, or if the submission pathway changes in a way that affects the basis for the designation. FDA will notify the sponsor before rescinding.

Does Breakthrough Device designation apply globally?

No. The designation is an FDA program and applies only to the U.S. regulatory process. It has no direct legal effect on CE marking in the EU, Health Canada licensing, or other jurisdictions. Some other regulatory agencies have analogous programs (for example, the MHRA's Innovative Licensing and Access Pathway in the UK), but they are separate applications.

How does Breakthrough Device designation interact with IDE requirements?

A designated device's IDE application, if required for clinical studies, receives priority review under the same framework. This means FDA can provide faster feedback on the IDE and engage interactively on clinical study design as part of the broader Breakthrough Device development program.

FDA Breakthrough Device Designation: What It Is and How to Apply

Direct answer: FDA's Breakthrough Devices Program is a voluntary designation that expedites the development and review of devices intended to provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. Designation delivers priority access to senior FDA reviewers, interactive review during development, and prioritized review of premarket submissions including 510(k), De Novo, and PMA. FDA must respond to a Breakthrough Device designation request within 60 calendar days. As of September 30, 2024, FDA had granted 1,041 designations, of which 128 had reached the U.S. market; FDA's more recent cumulative figure is 1,246 designations through December 31, 2025. (As of July 2026.)

The Breakthrough Devices Program was created under the 21st Century Cures Act (Public Law 114-255) and is codified at Section 515B of the FD&C Act (21 U.S.C. 360e-3). It is administered by FDA's Center for Devices and Radiological Health (CDRH). The program is voluntary: applying for designation is the manufacturer's choice, FDA reviews the request, and the designation, if granted, applies to all subsequent regulatory interactions for that specific device.

The program is not a separate regulatory pathway. A device designated as a Breakthrough Device still follows the standard 510(k), De Novo, or PMA pathway appropriate for its device classification. What changes is how FDA interacts with the sponsor during that process: more frequently, more substantively, and with greater access to senior decision-makers.

The program builds on earlier FDA programs including the Priority Review and Expedited Access Pathway programs, replacing and consolidating them under a single framework that applies across all device types and submission pathways.

Eligibility Criteria: Does Your Device Qualify?

To qualify for Breakthrough Device designation, a device must meet two criteria, both of which must be satisfied.

Criterion 1: More effective treatment or diagnosis

The device must provide for more effective treatment or diagnosis of a life-threatening or irreversibly debilitating disease or condition. FDA interprets "more effective" broadly. It can mean the device provides a treatment option where none currently exists, the device offers a clinically meaningful advantage over existing approved or cleared alternatives, or the device enables diagnosis that is faster, more accurate, or less invasive than current methods in a way that meaningfully affects patient outcomes.

"Life-threatening" and "irreversibly debilitating" are defined by reference to FDA's existing frameworks from the drug and biologic contexts. Conditions like end-stage renal disease, advanced cancer, severe heart failure, blindness, and paralysis have been cited in FDA documentation as examples. FDA evaluates these terms case by case.

Criterion 2: Addresses an unmet clinical need

The device must represent an important advance in medical device technology, or represent a breakthrough technology, where no approved or cleared alternatives exist, or where existing alternatives are inadequate. FDA looks at the totality of available options in the disease area. If effective treatments or diagnostics exist, the burden is on the applicant to explain what clinical gap the device fills and why the clinical community considers that gap important.

FDA's guidance document on the Breakthrough Devices Program, available at fda.gov, provides the most current criteria interpretation.

What Designation Provides: The Benefits in Practice

Breakthrough Device designation changes the operational dynamics of FDA review in several concrete ways.

Priority review of regulatory submissions

All premarket submissions for a designated device, including Q-Sub meeting requests, IDE applications, and the marketing submission itself (510(k), De Novo, or PMA), receive priority placement in FDA's review queue. This does not override the statutory and MDUFA review goals, but it means FDA dedicates review resources sooner and assigns more experienced staff.

Interactive review during development

This is the most substantive benefit and the one most valuable to early-stage device companies. Under standard review, FDA's input on your device is primarily reactive: you submit, FDA responds. Under Breakthrough review, FDA staff engage interactively during the development phase. Sponsors can have ongoing dialogue with reviewers about study designs, testing protocols, clinical endpoint selection, and manufacturing questions before the formal submission is filed.

For a small company building toward its first PMA, this interactive access can save years of iterative submissions. For a 510(k) candidate, it can clarify exactly what data package will be sufficient before the company invests in building it.

Assigned FDA case manager

Each designated device is assigned an FDA case manager who serves as a single point of contact across all regulatory interactions. This eliminates the common problem of different answers from different reviewers on the same question.

Prioritized access to senior FDA staff

The program provides rapid access to senior FDA reviewers and scientists for complex questions. In practice, this means that substantive technical disputes can be elevated and resolved faster than through the standard administrative appeal process.

How Breakthrough Designation Interacts with Each Pathway

510(k)

Most 510(k) devices will not meet the Breakthrough Device eligibility criteria because they are not treating life-threatening or irreversibly debilitating conditions. But for Class II devices in high-stakes disease areas (such as oncology diagnostics, advanced cardiac monitoring, or neurostimulation), breakthrough designation is possible. For eligible devices, designation means priority review within the 510(k) Total Time to Decision goal of 112 calendar days (as of July 2026 under MDUFA V for FY2025 through FY2027), with interactive engagement during the development of the predicate comparison and the performance data package.

De Novo

The De Novo pathway, which establishes new device types for novel Class II devices without a predicate, is frequently cited in breakthrough device contexts because novel devices often address unmet needs in serious diseases. Breakthrough designation can streamline the interactive review that De Novo requires, given that De Novo submissions require FDA to develop new special controls and the process is inherently more complex than a standard 510(k). FDA's review goal for De Novo is 150 calendar days (as of July 2026 under MDUFA V).

PMA

The PMA pathway applies to Class III devices, and PMA submissions are the most common context in which Breakthrough Device designation provides its most visible benefit. PMA applications require clinical data, and the ability to interact with FDA during clinical trial design, endpoint selection, and statistical analysis planning can significantly reduce the number of required additional study cycles. The interactive review benefit is most valuable for first-in-class PMA devices where FDA and the sponsor are both building the evidentiary framework from scratch.

The Application Process

When to apply

Apply for Breakthrough Device designation early, ideally before or shortly after entering clinical development. The benefits of interactive review are most valuable during study design; applying after clinical data is collected means you miss the most substantive advantage the program offers.

How to submit the request

The Breakthrough Device designation request is submitted as a Pre-Submission (Q-Sub) to CDRH. It does not require a full device application. The request should include a description of the disease or condition the device addresses, an explanation of how the device meets the life-threatening or irreversibly debilitating criterion, a description of the unmet clinical need and the limitations of existing alternatives, a description of the device and its intended use, and references to clinical literature supporting the unmet need characterization.

FDA's response timeline

FDA must respond to a Breakthrough Device designation request within 60 calendar days of receipt (as of July 2026, per Section 515B(d) of the FD&C Act, a statutory deadline). FDA will grant the designation, deny it with an explanation, or request additional information. If denied, sponsors can revise and resubmit.

What happens after designation

After designation is granted, the sponsor and FDA schedule an initial meeting to discuss the development program, the anticipated submission pathway, and the interactive review schedule. The sponsor then drives the cadence of future interactions within the framework FDA's workload permits.

Designation does not guarantee clearance or approval. It guarantees process: faster access, more dialogue, and a dedicated reviewer. The device still must demonstrate safety and effectiveness through whatever data standard applies to its pathway.

The Realistic Picture: Designation vs. Market

As of September 30, 2024, FDA had granted 1,041 Breakthrough Device designations, of which 128 devices had reached the U.S. market. FDA's more recent cumulative figure is 1,246 designations through December 31, 2025 (per FDA's Breakthrough Devices Program metrics). The gap between designation and market reflects the reality that designation is granted early in development, and many devices take years from designation to submission. It also reflects the inherent difficulty of clinical development for life-threatening disease categories. Breakthrough designation is an accelerant, not a shortcut.

Is the Breakthrough Devices Program Right for Your Device?

The program is most valuable when all of the following are true: the device targets a life-threatening or irreversibly debilitating condition, clinical development involves novel endpoints or a disease area where FDA has limited precedent, the company is navigating a PMA or a complex De Novo, and the company has the regulatory bandwidth to engage in substantive FDA interactions during development (not all early-stage companies do).

For a straightforward 510(k) with a clear predicate in a well-established device category, the Breakthrough Devices Program adds little and the application effort may not be warranted.

If the program could apply to your device, a well-structured Pre-Submission meeting to test the eligibility argument costs little and can clarify your path significantly. The Buzzbox Media team has worked with device companies across the market development, commercialization, and launch phases, and we understand how Breakthrough status shapes the marketing and commercial timeline. See our medical device marketing services for how we support teams from clearance through commercial launch.